April 22, 2025
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities
United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964
Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country
Roche (company), Indiana, United States, Investments, expansion, Pennsylvania, Expanding, upgrade, Research Organization
Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies
Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies
Dupixent notches seventh disease approval with urticaria nod
Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal
Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival